Literature DB >> 29678336

Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy.

Dai-Yin Lu1, Hulya Yalçin2, Fatih Yalçin2, Min Zhao3, Sanjay Sivalokanathan2, Ines Valenta3, Abdel Tahari3, Martin G Pomper3, Theodore P Abraham4, Thomas H Schindler3, M Roselle Abraham5.   

Abstract

Patients with hypertrophic cardiomyopathy (HC) are at increased risk of sudden cardiac death. Abnormalities in myocardial blood flow (MBF) detected by positron emission tomography (PET) are common in HC, but a PET marker that identifies patients at risk of sudden cardiac death is lacking. We hypothesized that disparities in regional myocardial perfusion detected by PET would identify patients with HC at risk of ventricular arrhythmias. To test this hypothesis, we quantified global and regional MBFs by 13NH3-PET at rest and at stress, and developed a heterogeneity index to assess MBF heterogeneity in 133 symptomatic patients with HC. The MBF heterogeneity index was computed by dividing the highest by the lowest regional MBF value, at rest and after vasodilator stress, in each patient. High stress MBF heterogeneity was defined as an index of ≧1.85. Patients with HC were stratified by the presence or the absence of ventricular arrhythmias, defined as sustained ventricular tachycardia (VT) and/or nonsustained VT, during follow-up. We found that global and regional MBFs at rest and stress were similar in patients with HC with or without ventricular arrhythmias. Variability in regional stress MBF was observed in both groups, but the stress MBF heterogeneity index was significantly higher in patients with HC who developed ventricular arrhythmias (1.82 ± 0.77 vs 1.49 ± 0.25, p <0.001). A stress MBF heterogeneity index of ≧1.85 was an independent predictor of both sustained VT (hazard ratio 16.1, 95% confidence interval 3.2 to 80.3) and all-VT (sustained-VT + nonsustained VT: hazard ratio 3.7, 95% confidence interval 1.4 to 9.7). High heterogeneity of stress MBF, reflected by an MBF heterogeneity index of ≥1.85, is a PET biomarker for ventricular arrhythmias in symptomatic patients with HC.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29678336      PMCID: PMC5966031          DOI: 10.1016/j.amjcard.2018.01.022

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Perry M Elliott; Juan R Gimeno; María T Tomé; Jaymin Shah; Deirdre Ward; Rajesh Thaman; Jens Mogensen; William J McKenna
Journal:  Eur Heart J       Date:  2006-06-05       Impact factor: 29.983

2.  Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal.

Authors:  Helga Castagnoli; Cecilia Ferrantini; Raffaele Coppini; Alessandro Passeri; Katia Baldini; Valentina Berti; Franco Cecchi; Iacopo Olivotto; Roberto Sciagrà
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-16       Impact factor: 9.236

3.  Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy.

Authors:  Paco E Bravo; Stefan L Zimmerman; Hong-Chang Luo; Iraklis Pozios; Mahadevan Rajaram; Aurélio Pinheiro; Charles Steenbergen; Ihab R Kamel; Richard L Wahl; David A Bluemke; Frank M Bengel; M Roselle Abraham; Theodore P Abraham
Journal:  Circ Cardiovasc Imaging       Date:  2013-02-15       Impact factor: 7.792

4.  Coupling of cell energetics with membrane metabolic sensing. Integrative signaling through creatine kinase phosphotransfer disrupted by M-CK gene knock-out.

Authors:  M Roselle Abraham; Vitaliy A Selivanov; Denice M Hodgson; Darko Pucar; Leonid V Zingman; Be Wieringa; Petras P Dzeja; Alexey E Alekseev; Andre Terzic
Journal:  J Biol Chem       Date:  2002-04-19       Impact factor: 5.157

5.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

6.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

7.  A simplified method for quantification of myocardial blood flow using nitrogen-13-ammonia and dynamic PET.

Authors:  Y Choi; S C Huang; R A Hawkins; W G Kuhle; M Dahlbom; C K Hoh; J Czernin; M E Phelps; H R Schelbert
Journal:  J Nucl Med       Date:  1993-03       Impact factor: 10.057

8.  Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies.

Authors:  Rajiv Sankaranarayanan; Eleanor J Fleming; Clifford J Garratt
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-04

9.  Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction.

Authors:  Sairia Dass; Lowri E Cochlin; Joseph J Suttie; Cameron J Holloway; Oliver J Rider; Leah Carden; Damian J Tyler; Theodoros D Karamitsos; Kieran Clarke; Stefan Neubauer; Hugh Watkins
Journal:  Eur Heart J       Date:  2015-05-18       Impact factor: 29.983

Review 10.  Anatomy and physiology of coronary blood flow.

Authors:  Heinrich R Schelbert
Journal:  J Nucl Cardiol       Date:  2010-08       Impact factor: 5.952

View more
  9 in total

1.  Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?

Authors:  G Neal Kay
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

Review 2.  Role of nuclear cardiology in diagnosis and risk stratification of coronary microvascular disease.

Authors:  Terrence D Ruddy; Anahita Tavoosi; Viviany R Taqueti
Journal:  J Nucl Cardiol       Date:  2022-07-18       Impact factor: 3.872

Review 3.  Assessment and Treatment for Coronary Microvascular Dysfunction by Contrast Enhanced Ultrasound.

Authors:  Junzhen Zhan; Longhe Zhong; Juefei Wu
Journal:  Front Cardiovasc Med       Date:  2022-06-20

4.  Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Authors:  Paco E Bravo
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

Review 5.  Multimodality imaging predictors of sudden cardiac death.

Authors:  Fancesco Bandera; Lilit Baghdasaryan; Giulia Elena Mandoli; Matteo Cameli
Journal:  Heart Fail Rev       Date:  2020-05       Impact factor: 4.214

6.  Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy.

Authors:  Yamin Liu; Junaid Afzal; Styliani Vakrou; Gabriela V Greenland; C Conover Talbot; Virginia B Hebl; Yufan Guan; Rehan Karmali; Jil C Tardiff; Leslie A Leinwand; Jeffrey E Olgin; Samarjit Das; Ryuya Fukunaga; M Roselle Abraham
Journal:  Front Cardiovasc Med       Date:  2019-12-17

Review 7.  Coronary Microvascular Dysfunction: PET, CMR and CT Assessment.

Authors:  Elisabetta Tonet; Graziella Pompei; Evelina Faragasso; Alberto Cossu; Rita Pavasini; Giulia Passarini; Matteo Tebaldi; Gianluca Campo
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

8.  Positron emission tomography (15O-water, 11C-acetate, 11C-HED) risk markers and nonsustained ventricular tachycardia in hypertrophic cardiomyopathy.

Authors:  Peter Magnusson; Jonny Nordström; Hendrik J Harms; Mark Lubberink; Fredrik Gadler; Jens Sörensen; Stellan Mörner
Journal:  Int J Cardiol Heart Vasc       Date:  2019-12-20

9.  Correlations between cardiac troponin I and nonsustained ventricular tachycardia in hypertrophic obstructive cardiomyopathy.

Authors:  Limin Liu; Shangyu Liu; Lishui Shen; Bin Tu; Zhicheng Hu; Feng Hu; Lihui Zheng; Ligang Ding; Xiaohan Fan; Yan Yao
Journal:  Clin Cardiol       Date:  2020-08-18       Impact factor: 2.882

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.